Many Medicare Part D Stand-Alone Drug Plan Enrollees Will See Modest Premium Increases for 2027, But Others Could Pay Much More If They Don’t Switch Plans

This brief analyzes the Medicare Part D stand-alone prescription drug plan (PDP) market for 2027. The analysis shows that there will be a modest reduction in the number of PDPs for 2027, along with modest premium increases less than $10 per month for many enrollees, but much larger monthly premium increases of $50 or more…

Read More

Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines

Gilead Sciences exercised its option license a Kymera Therapeutics’ protein-degrading drug designed to eliminate the cancer-driving protein CDK2. Meanwhile, Roche’s new partnership with C4 Therapeutics is focused on developing degrader antibody drug conjugates for undisclosed cancer targets. The post Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines appeared first on MedCity…

Read More

Pennsylvania Sues Chatbot Over Claims It Impersonates Doctors

Pennsylvania sued Character.ai, alleging one of the startup’s AI chatbots illegally practiced medicine by posing as a licensed psychiatrist. The case marks the second state lawsuit against the startup and highlights growing regulatory scrutiny of AI chatbot platforms and their safety guardrails. The post Pennsylvania Sues Chatbot Over Claims It Impersonates Doctors appeared first on…

Read More